Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer

HER2-positive and Triple-negative are subtypes of breast cancer more sensitive to systemic therapies, where the complete pathological response rate may be higher than 50%. This gave rise to doubts about the usefulness of traditional local treatments for such responders. Omission of surgery after vacuum assisted breast biopsy (VABB) as well omission of radiotherapy after conservative surgery would now seem to be reasonable alternatives to standard care for highly selected patients, in whom systemic treatments have provided the maximum response.

NCT Number	NCT06938724
Lead Sponsor	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Conditions	Breast Neoplasm Malignant Female
Enrollment	152 participants
Start Date	2025-07-25
Primary Completion	2035-07-25 (estimated)
Study Completion	2035-07-25 (estimated)
Updated on ClinicalTrials.gov	2025-09-15